touchONCOLOGY touchONCOLOGY
Play ArrowPlay Video

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Outcomes in patients with brain metastases
   
Outcomes in high-risk patients
   
Role of biomarkers in personalizing treatment
   
Overall survival rates for combination approaches
   

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

Which of the following treatments is most likely to change your clinical practice?

Submit your answer to see the results

Osimertinib + chemotherapy
   
Amivantamab + lazertnib
   
Amivantamab + chemotherapy
   
Other
   

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

Which is the most important area for research in late-stage EGFR-mutant NSCLC?

Submit your answer to see the results

Management of CNS metastases/leptomeningeal disease
   
Biomarkers to monitor/predict treatment response
   
Identifying patients for risk-adaptive treatment strategies
   
Understanding specific resistance mutations
   
Play ArrowPlay Video

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Outcomes in patients with brain metastases
   
Outcomes in high-risk patients
   
Role of biomarkers in personalizing treatment
   
Overall survival rates for combination approaches
   

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

Which of the following treatments is most likely to change your clinical practice?

Submit your answer to see the results

Osimertinib + chemotherapy
   
Amivantamab + lazertnib
   
Amivantamab + chemotherapy
   
Other
   

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

Which is the most important area for research in late-stage EGFR-mutant NSCLC?

Submit your answer to see the results

Management of CNS metastases/leptomeningeal disease
   
Biomarkers to monitor/predict treatment response
   
Identifying patients for risk-adaptive treatment strategies
   
Understanding specific resistance mutations
   
Play ArrowPlay Video

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Outcomes in patients with brain metastases
   
Outcomes in high-risk patients
   
Role of biomarkers in personalizing treatment
   
Overall survival rates for combination approaches
   

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

Which of the following treatments is most likely to change your clinical practice?

Submit your answer to see the results

Osimertinib + chemotherapy
   
Amivantamab + lazertnib
   
Amivantamab + chemotherapy
   
Other
   

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

Which is the most important area for research in late-stage EGFR-mutant NSCLC?

Submit your answer to see the results

Management of CNS metastases/leptomeningeal disease
   
Biomarkers to monitor/predict treatment response
   
Identifying patients for risk-adaptive treatment strategies
   
Understanding specific resistance mutations
   

touchCLINICAL PERSPECTIVES
A modular programme that includes a variety of interviews with experts and a patient, as well as downloadable resources. Close

Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease

Claim Credit

Part 1 ー EGFR-mutant NSCLC: Navigating the horizon in EGFR-mutant NSCLC

Dr Helena Yu, course director and thoracic oncologist, discusses the unmet needs of patients with EGFR-mutant metastatic non-small cell lung cancer (NSCLC) by highlighting the current challenges, areas for further research and clinical trial landscape.

After watching this activity, participants should be better able to:

  1. Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing.

Part 2 ーEGFR-mutant NSCLC: Evaluating the latest advances in therapeutic strategies

Dr Antonio Passaro, an oncologist specializing in lung cancer, provides insights into the latest advances in therapeutic strategies for EGFR-mutant metastatic non-small cell lung cancer (NSCLC), focusing on recent clinical trial data in both the first- and second-line settings.

After watching this activity, participants should be better able to:

  1. Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing.

Part 3 ーEGFR-mutant NSCLC: Practical insights and implications for NSCLC practice

Dr Helena Yu provides an overview of the current treatment options for EGFR-mutant metastatic non-small cell lung cancer (NSCLC). She uses a patient case to explore both the existing therapies available at diagnosis and at the point of disease progression, as well as how ongoing research and the advent of new therapies and combination strategies might impact future treatment approaches.

After watching this activity, participants should be better able to:

  1. Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing.
  2. Use knowledge of efficacy and safety data for current and emerging first- and second-line treatments in patients with EGFR-mutant and wildtype NSCLC to develop optimal care pathways and improved clinical outcomes.

Modules

Coming Soon

Module 2 - Part 1:
Advances in the treatment landscape for EGFR-wildtype NSCLC

Coming Soon

Module 2 - Part 2:
Insights from the latest data and strategies for improvement

Coming Soon

Module 2 - Part 3:
Practical insights and implications for NSCLC practice

Coming Soon

Module 3 - Part 1:
Novel strategies, care pathways and side effect management

Coming Soon

Module 3 - Part 2:
Implications of novel treatments on the shifting biomarker landscape

Coming Soon

Module 3 - Part 3:
Optimizing outcomes in late-stage NSCLC: Key learnings

Topics covered in this activity

Haematology / Rare Diseases
REGISTER NOW FOR FREE ACCESS TO
  • 1000+ topical and insightful peer-reviewed journal articles
  • 1000+ topical and insightful peer-reviewed journal articles
  • 10 major therapy areas packed with the latest scientific advances
  • 150+ specialties offering learn-on-the-go medical education
  • + Concise email updates and newsletters so you never miss out
Register For Free Now
Claim Credit
touchCLINICAL PERSPECTIVES
Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease
0.5 CE/CME credit

Question 1/2
Which of the following statements best reflects the recent outcomes of the FLAURA2 trial evaluating osimertinib ± Pt-ChT in EGFR-mutant NSCLC?

AE, adverse event; CNS, central nervous system; EGFR, epidermal growth factor receptor; PFS, progression-free survival; Pt-ChT, platinum-based chemotherapy.

The phase III FLAURA2 study, investigating osimertinib ± Pt-ChT in EGFR-mutant advanced NSCLC, demonstrated a median PFS of 25.5 months in the overall population receiving the combination vs 16.7 months in patients receiving osimertinib alone (HR 0.62; 95% CI 0.49–0.79; p<0.001). A PFS benefit in favour of the combination group was observed across prespecified subgroup populations, including patients with an exon 19 deletion, exon 21 (L858R) mutation, with CNS metastases and without CNS metastases. The rate of grade ≥3 AEs was higher in the combination group than the osimertinib monotherapy group (64 vs 27%).

Abbreviations
AE, adverse event; CI, confidence interval; CNS, central nervous system; EGFR, epidermal growth factor receptor; HR, hazard ratio; NSCLC, non-small cell lung cancer; PFS, progression-free survival; Pt-ChT, platinum-based chemotherapy.

Reference
Planchard D, et al. N Engl J Med. 2023;389:1935–48.

Question 2/2
Your patient is a 54-year-old woman with a stage IV EGFR-mutant NSCLC harbouring an exon 19 deletion mutation. Following administration of osimertinib QD for a period of 18 months, she has evidence of disease progression with the development of brain metastases. Which of the following agents might you select based on recent clinical trial data (and providing all agents are available) that could be added to the standard of care chemotherapy in the second-line setting to improve your patient’s outcomes?

EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; QD, once daily.

The phase III MARIPOSA-2 evaluated intravenous amivantamab + chemotherapy with or without lazertinib vs chemotherapy alone in patients with EGFR-mutant advanced NSCLC after disease progression on osimertinib. PFS was significantly longer with amivantamab + chemotherapy vs chemotherapy alone in all randomized patients (HR 0.48; 95% CI 0.36–0.64; p<0.001) and in patients with a history of brain metastasis (HR 0.52; 95% CI 0.35–0.78).1  

The PFS was also significantly longer in the amivantamab + lazertinib + chemotherapy arm vs chemotherapy alone (HR 0.44, 95% CI 0.35-0.56, p< 0.001). However, AEs of grade 3 or higher, mainly due to haematologic toxicities, were higher in the amivantamab + lazertinib + chemotherapy arm vs both amivantamab + chemotherapy and chemotherapy alone, which led to a regimen change during the trial for the triplet therapy arm.1 Longer follow-up is required for this modified regimen.

The antibody–drug conjugate patritumab deruxtecan has been evaluated as a third- or later-line monotherapy agent only in patients who had previously been treated with osimertinib and one or more prior lines of chemotherapy in the HERTHENA-Lung01 study.2 

Abbreviations

AE, adverse event; CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; NSCLC, non-small cell lung cancer; PFS, progression-free survival. 

References

  1. Passaro A, et al. Ann Oncol. 2024;35:77–90.
  2. Yu HA, et al. J Clin Oncol. 2023;41:5363–75.
Back to Activity
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72